Evaluation of influence of systemie adjuvant chemotherapy applied according to modified scheme
MVAC on survival of patients treated for invasive bladder cancer Article published in Urologia Polska 2002/55/1.
authors
-
Wojciech Kołaczyk 1, Janusz Dembowski 2, Jerzy Lorenz 2, Krzysztof Dudek 3
- 1 Oddział Urologii Szpitala Wojewódzkiego w Legnicy
Ordynator oddziału: dr Wojciech Kołaczyk
2 Katedra i Klinika Urologii Akademii Medycznej we Wrocławiu
Kierownik kliniki: prof, dr hab. Jerzy Lorenz
3 Zakład Inżynierii Niezawodności i Diagnostyki Politechniki we Wrocławiu
keywords
-
bladder, invasive bladder cancer, systemie chemotherapy
summary
- Purpose. The aim of the paper was assesement of influence of adjuvant systemic chemotherapy applied according to modified
- scheme MVAC in patients treated for invasive bladder cancer. Materials and methods. We retrospectively reviewed two groups: the first one included patients who received chemotherapy
- Group A - 26) after cystectomy, and second one included patients treated only with surgery (Group K-62 patients). The average time of observation was 3,2 years (aximum 10 years 3 months, minimum 3 months). The patients in main group were divided into two subgroups: the first one included patients where tumour was confined to bladder (Tl+T2+T3a), and the second was made up the remaining patients where tumor expanded behind the bladder (T3b+T4a+b
- The Results. In Group A we didn\'t observe survival rate longer than 5 years. The survival rate in Group K was 57,4% wheras in Group A - 41,4%. We didn\'t observe statistical differences in survival rate in patients with changes in lymph nodes. In group of patients without changes in lymph nodes and where tumour was confined to bladder, 5 years survival in the Group A was 51,4%, whereas in Group K- 93%.
- Conclusion. Systemic adjuvant chemotherapy does not influence the survival of patients treated for invasive bladder cancer.
references
- 1. Angulo JC, Sanchez-Chapado M, Grignon DJ, Montic JE. Pontes EJ: Radical cystectomy in node positive bladder cancer. Multivariate analysis on prognostic factors. Eur Urol 1996; 30 S2, 267, abstr. 1003.
- 2. Ashamallah A, El-Mekresh MM, El-Baz MA, Elatar IA, Gho-neini MA: Radical cystectomy for carcinoma of the urinary bladder: critical evaluation of the results in 1026 cases. Brit J Urol, 1997, 49, abstr. 190.
- 3. Dinney CPN, Perrotte P, Slaton JW: Impact of adjuvant chemotherapy on longterm survival ofpatints with lymph node metastases after radical cystectomy. J Urol 159; 5; 166, abstr. 635.
- 4. Freiha F, Reese J, Torti FM: A randomised trial of radical cyslectomy and radical cystectomy plus cisplalin, vinblastine, and methotrexate chemoierapy for muscle invasive bladder cancer. J Urol 1996; 155; 495-500.
- 5. Logothetis C, Johnson DE, Chong C, Dexeus FH, Sella A, Ogden S, Smith T, Swanson DA, Babaian RJ, Wishnow KI, Eschenbach von AC: Adjuvant cyclophosphamide, doxorubicin and cisplalin chemotherapy for bladder cancer: an update. J Clin Oncol 1988; 6; 1560,
- 6. Logolhetis C, Swanson D, Amato R: Optimal delivery of perioperative chemotherapy: Preliminary results of randomized, prospective comperative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma. Cancer 1992; 69; 2767-2769,
- 7. Otlo T, Boergmann C, Krege S, Ruebben II and Participating Clinicans: Adjuvant chemotherapy in locally advanced bladder cancer [PT3/PN1-2, MO] a phase III study. Eur Urol 2001; (suppl 5); 147.
- 8. Ruebben H, Otto T: Loka! forigeschrittenes oder metastusiertes Hamblasencarcinom. Urologie 2001: 40; 464-467.
- 9. Schulz-Lampel D, Lampel A: Neo-adjuvant and adjuvant treatment for locally invasive bladder cancer. Cur Op Urol 1999; 9; 419-424.
- 10. Skinner DG, Daniels R, Russel CA, Leiskovsky G, Boyd SD, Nichols P, Kern W, Sakamoto J, Krailo M, Groshen S: The role adjuvant chemotherapy following cystectomy for invasive bladder cancer: prospective trial. J Urol 1991; 145; 459-467.
- 11. Skinner DG, Slein JR Leiskovsky G, Skinner EC, Boyd SD, Fi-gucroa A, Jones P, Cole R, Groshen S: 25-year experience in the management of invasive bladder cancer by radical cystectomy. Eur Urol 1998; 33 (suppl. 4); 25-26.
- 12. Stoeckle M, Mcyenburg M, Wellek S et al: Advanced bladder cancer (stages pT3b, pT4a, pNl and pN2): improved survival after radical cystectomy and 3 adjuvant cycles chemotherapy. Results of a controlled prospective study. J Urol 1992; 148; 302-307.
- 13. Sluder UE, Bacchi M, Biedermann C: Adjuvant cisplalin chemotherapy following cystectomy for bladder cancer. Results of a prospective randomised trial. J Urol 1994; 152; 81-84.
- 14. Wei Chih-Hsin, Hsieh Ruey-Kucn, Chiou Tzeon-Jye, Chen Kuang-Kuo, Chang Luke S, Chen Po-Min: Adjuvant methotrexate, vinblastine and cisplalin chemotherapy for invasive transitional cell carcinoma: Taiwan experience. J Urol 1996; 155; 118-121.
- 15. Woehr M, Echtle D, Westermann D, Kontaxis D, Mueller E, Frohneberg D: Survival, lypmph node status and adjuvant chemotherapy. Eur Urol 2001 (suppl 5); 145.
correspondence
Wojciech Kolaczyk
Szpital Wojewódzki Oddział Urologii
ul. Iwaszkiewicza 5
76 - 866 Legnica
|